In this prospective cohort study, we firstly investigated to evaluate the efficacy and safety of inetetamab + pertuzumab + taxanes + carboplatin (TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally advanced HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.